Medscape5d
Durvalumab Is Not Superior to Cetuximab in Head, Neck Cancer
Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...
The American Journal of Managed Care23d
Durvalumab Approval Redefines Resectable NSCLC Treatment Strategies
In this interview, Martin Dietrich, MD, PhD, thoracic oncologist with The US Oncology Network and Cancer Care Centers of Brevard, discusses durvalumab’s transformative impact on NSCLC treatment ...
Monthly Prescribing Reference1mon
Durvalumab Gets Priority Review for Muscle-Invasive Bladder Cancer
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
Joplin Globe1mon
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
Immune-mediated rash or dermatitis occurred in 1.8% (34/ ... Europe and Asia. IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction ...
MedPage Today1mon
Durvalumab Wins FDA Approval in Limited-Stage SCLC
Opens in a new tab or window The FDA expanded the indications for the immune checkpoint inhibitor durvalumab (Imfinzi) to include limited-stage small cell lung cancer (SCLC). Approval stipulates ...
Morningstar1mon
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...
Enid News & Eagle1mon
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Dec 5, 2024-- ...